Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) reported third-quarter 2019 earnings of $2.79 per share, vs. $2.47 per share expected.
Revenues grew 23% to $1.26 billion, vs. $1.24 billion expected. Sales of SOLIRIS (eculizumab) came in at $990.5 million, up 12% year-over-year.
Raised FY19 revenue guidance to $4.86 – $4.89 billion vs. prior guidance of $4.75 – $4.8 billion billion.
Adjusted EPS guidance for FY19 raised to a new range of $10.25 – $10.40, vs. earlier guidance of $9.65 – $9.85.
ALXN shares rose 1.7% immediately following the announcement.
Most Popular
Chewy (CHWY): Three factors that work in favor of this pet retailer
Shares of Chewy, Inc. (NYSE: CHWY) gained over 1% on Monday. The stock has dropped 10% in the past three months. The pet products seller delivered solid results for the
Earnings Preview: Will cost pressures impact Darden Restaurants’ Q2 results?
Darden Restaurants, Inc. (NYSE: DRI), a full-service restaurant operator, has faced margin pressure this year from higher input costs tied to tariffs on key commodities. Despite that, management remains optimistic,
NKE Q2 Earnings Preview: Can Nike maintain the recovery momentum?
Sneaker giant NIKE, Inc. (NYSE: NKE) entered the fiscal year facing heightened competition and shifting consumer preferences. Its upcoming second-quarter results are expected to reflect these evolving industry dynamics and
Comments